Sanofi SA


  • Sanofi tanks 7.4% on diabetes business warning Tuesday, 28 Oct 2014 | 4:31 AM ET

    Shares of Sanofi tumbled around 7.4 percent early on Tuesday after the French drugmaker reported weaker-than-expected Q3 sales.

  • European shares rise early; Sanofi sinks Tuesday, 28 Oct 2014 | 4:08 AM ET

    PARIS, Oct 28- European shares rose in early trade on Tuesday, reversing the previous session's dip as better-than-expected results from a number of blue-chips including pharma group Novartis and bank UBS helped lift sentiment. At 0803 GMT, the FTSEurofirst 300 index of top European shares was up 0.6 percent at 1,313.05 points, with UBS up 1.9 percent and...

  • LONDON, Oct 27- Drugmakers sprinting to develop Ebola vaccines face a series of technical hurdles if they are to get millions of doses ready for use next year-- even assuming clinical trials are successful. The challenges include finding sufficient sterile capacity for filling and packaging finished vials, getting fast quality approvals from regulators, and...

  • BUSINESS-NEWS-SCHEDULE AT 0930 GMT /5.30 AM ET Monday, 27 Oct 2014 | 6:02 AM ET

    Monte dei Paschi drags Europe's banks lower post-stress test. LONDON- Italy's Monte dei Paschi slumps after having the biggest capital hole to fill in a health check of European banks that was generally seen as good news for the sector. BERLIN- German business sentiment darkens in October for a sixth month running, hitting its lowest level in almost two years and...

  • Oct 20- Generic drugmaker Actavis Plc and France's Sanofi SA are among the suitors for privately held Omega Pharma NV, Bloomberg reported, citing people familiar with the matter. Other bidders for the Belgian consumer healthcare company include Perrigo Co and private German drugmaker Boehringer Ingelheim GmBH, the sources told Bloomberg.

  • Positive for Regeneron: Cramer  Friday, 17 Oct 2014 | 9:55 AM ET

    CNBC's Jim Cramer discusses news Regeneron's drug Eylea for treating diabetic macular edema created significantly greater improvement in visual acuity compared with Lucentis.

  • LONDON, Oct 14- GlaxoSmithKline is seeking binding bids by next month for a range of older drugs worth more than $3 billion, which it is likely to sell by geographical region, according to people with direct knowledge of the process. Britain's biggest drug maker is looking to divest the mature products in a bid to improve its growth profile and wants to dispose of...

  • NEW YORK, Oct 8- Earlier this week, Canada's Valeant Pharmaceuticals International Inc appeared to have its plan to buy Botox maker Allergan Inc all mapped out. However, Valeant's well-laid plans appeared to run into trouble this week, when rival drugmaker Actavis Plc came back into the picture as a possible white knight for Allergan. Meanwhile, a separate person...

  • GSK investigating corruption allegations in UAE Wednesday, 8 Oct 2014 | 1:17 AM ET

    GlaxoSmithKline, which was slapped with a record fine for corruption in China, said it was looking into allegations of corruption in UAE.

  • *GSK says UAE investigations part of wider Middle East probe. LONDON, Oct 7- Drugmaker GlaxoSmithKline, which was slapped with a record $489 million fine for corruption in China last month, said on Tuesday it was looking into allegations of corruption in the United Arab Emirates. The company is already investigating alleged bribery in a number of Middle East...

  • LONDON, Oct 6- AstraZeneca's blood-thinning drug Brilinta has won preferred status in the United States, where two medical groups have recommended it over the older drug Plavix, also known as clopidogrel. AstraZeneca said on Monday it was the first time the cardiology organizations had recommended one drug of this type over another in the treatment of acute...

  • NEW YORK, Oct. 1- Two tiny companies are preparing to challenge some of the world's largest drug makers in the battle for dominance in the $3 billion global market for influenza vaccines, armed with little more than tiny tobacco plants.

  • LONDON, Sept 25- European shares slipped to a one-month low in late trading on Thursday, tracking a sell-off in U.S. stocks, as a stronger dollar undercut prices for industrial metals, causing mining shares to drop.

  • European shares fall in late sell-off, miners slip Thursday, 25 Sep 2014 | 11:23 AM ET

    *FTSE 100 underperforms on concerns of rate hike. The STOXX Europe 600 Basic Resources index fell 2.1 percent to feature as the biggest sectoral decliner in Europe after prices of key base metals fell following a rise in the dollar index, which measures the greenback against a basket of major currencies, to a four-year high.

  • NEW YORK, Sept 25- MannKind Corp shares were among the most actively traded in premarket on Thursday, after the company said it had closed a licensing agreement with Sanofi for the development and commercialization of its inhaled insulin product. MannKind said it will receive a $150 million upfront payment within 10 days of the closing.

  • European shares up, weaker euro seen boosting earnings Thursday, 25 Sep 2014 | 7:18 AM ET

    *Telecom Italia up on report businessman seeks finance for bid. LONDON, Sept 25- European shares extended the previous session's rebound on Thursday as a further drop in the euro fuelled expectations of a boost to the region's corporate earnings. Federal Reserve and the European Central Bank.

  • European shares inch higher as euro falls further Thursday, 25 Sep 2014 | 4:09 AM ET

    PARIS, Sept 25- European shares gained ground in early trade on Thursday, extending the previous session's rebound as a further drop in the euro fuelled expectations of a boost to the region's corporate earnings. Federal Reserve and the European Central Bank.

  • These 3 hot health-care stocks look strong: Pro Wednesday, 24 Sep 2014 | 2:49 PM ET

    Health-care stocks still have upside, Dan Chai of Iguana Healthcare Partners says.

  • The drug, developed by Vivus Inc, is marketed in the United States and Canada by Auxilium Pharmaceuticals Inc. Vivus' stock was up about 13 percent at $4.40 in afternoon trading.

  • The drug was developed by Auxilium Pharmaceuticals Inc and Vivus Inc.. Vivus owns the worldwide development and commercial rights to Stendra for use in sexual dysfunction, with the exception of certain Asian countries in the Pacific Rim.